But it does have to do with offshoring of activities. When the FDA spends 20 weeks at a US med device facility for an inspection and only 5 days each at facilities in China or India - then there is an overdue burden being placed on US facilities. THAT drives decisions.
Fair enough, but not relevant to the article.